Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study
Copyright policy )Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study
Abstract Background Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort. Methods Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940–2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated. Results In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50. Discussion Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms.
- University of Birmingham United Kingdom
- Amsterdam UMC Netherlands
- Kepler Universitätsklinikum Austria
- St Anna Children's Hospital Austria
- University of Turin Italy
Adult, Adolescent, Glioma/epidemiology, 610, 610 Medicine & health, Central Nervous System Neoplasms/epidemiology, Article, Europe/epidemiology, Leukemia/epidemiology, Central Nervous System Neoplasms, 360 Social problems & social services, Risk Factors, Meningeal Neoplasms, Humans, Meningioma/etiology, Survivors, Meningeal Neoplasms/epidemiology, Leukemia, Incidence, Humans; Adolescent; Adult; Middle Aged; Meningioma/etiology; Meningioma/complications; Risk Factors; Neoplasms, Second Primary/epidemiology; Neoplasms, Second Primary/etiology; Central Nervous System Neoplasms/epidemiology; Glioma/epidemiology; Survivors; Leukemia/epidemiology; Europe/epidemiology; Meningeal Neoplasms/epidemiology; Incidence, Neoplasms, Second Primary, Glioma, Middle Aged, Europe, Neoplasms, Second Primary/epidemiology, Meningioma, Adolescent [MeSH] ; /631/67/2324 ; Survivors [MeSH] ; Adult [MeSH] ; Meningeal Neoplasms/epidemiology [MeSH] ; Central Nervous System Neoplasms/epidemiology [MeSH] ; Humans [MeSH] ; Incidence [MeSH] ; Middle Aged [MeSH] ; Risk Factors [MeSH] ; /631/67/2332 ; Leukemia/epidemiology [MeSH] ; Europe/epidemiology [MeSH] ; Meningioma/complications [MeSH] ; Neoplasms, Second Primary/epidemiology [MeSH] ; /692/308/174 ; Article ; /692/499 ; Meningioma/etiology [MeSH] ; /631/67/1922 ; Neoplasms, Second Primary/etiology [MeSH] ; Glioma/epidemiology [MeSH] ; article
Adult, Adolescent, Glioma/epidemiology, 610, 610 Medicine & health, Central Nervous System Neoplasms/epidemiology, Article, Europe/epidemiology, Leukemia/epidemiology, Central Nervous System Neoplasms, 360 Social problems & social services, Risk Factors, Meningeal Neoplasms, Humans, Meningioma/etiology, Survivors, Meningeal Neoplasms/epidemiology, Leukemia, Incidence, Humans; Adolescent; Adult; Middle Aged; Meningioma/etiology; Meningioma/complications; Risk Factors; Neoplasms, Second Primary/epidemiology; Neoplasms, Second Primary/etiology; Central Nervous System Neoplasms/epidemiology; Glioma/epidemiology; Survivors; Leukemia/epidemiology; Europe/epidemiology; Meningeal Neoplasms/epidemiology; Incidence, Neoplasms, Second Primary, Glioma, Middle Aged, Europe, Neoplasms, Second Primary/epidemiology, Meningioma, Adolescent [MeSH] ; /631/67/2324 ; Survivors [MeSH] ; Adult [MeSH] ; Meningeal Neoplasms/epidemiology [MeSH] ; Central Nervous System Neoplasms/epidemiology [MeSH] ; Humans [MeSH] ; Incidence [MeSH] ; Middle Aged [MeSH] ; Risk Factors [MeSH] ; /631/67/2332 ; Leukemia/epidemiology [MeSH] ; Europe/epidemiology [MeSH] ; Meningioma/complications [MeSH] ; Neoplasms, Second Primary/epidemiology [MeSH] ; /692/308/174 ; Article ; /692/499 ; Meningioma/etiology [MeSH] ; /631/67/1922 ; Neoplasms, Second Primary/etiology [MeSH] ; Glioma/epidemiology [MeSH] ; article
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).5 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!